Evidence map›Paper›PMID 24287071›Full record

ReviewHematology/oncology clinics of North America2014

Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Catherine Diefenbach, Ranjana Advani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. HLA-G expression and role in advanced-stage classical Hodgkin lymphoma.European journal of histochemistry : EJH · 2016
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Catherine DiefenbachDepartment of Medicine, New York University School of Medicine/New York University Cancer Center, 240 East 38th Street, New York, NY 10016, USA.
Ranjana Advani

Funding

Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2012 to 2014
$16.8M
NCATS NIH HHS UL1 TR000038NCATS NIH HHS UL1 TR00038
6 · The paper itself

Abstract

Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unraveling the biology of HL have yielded a plethora of novel targeted therapies. This review provides an overview of the data behind the hype generated by these advances and addresses the question of whether or not clinically these targeted therapies offer hope for patients with HL.

Indexed as

Molecular Targeted TherapyAntibodies, MonoclonalAntineoplastic AgentsHodgkin DiseaseHumansImmunotherapy, AdoptiveKi-1 AntigenSignal TransductionTumor MicroenvironmentAntibodies, MonoclonalAntineoplastic AgentsKi-1 AntigenBrentuximab vedotinHodgkin lymphomaRelapsed diseaseTargeted therapies

Identifiers

PMID24287071
PMCPMC4023679

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.